Urologic complications of nonurologic medications

Urologic Clinics of North America

Volumn 30, Issue 1, 2003, Pages 123-131

  Thomas, Arthur ^a   Woodard, Christopher ^a   Rovner, Eric S ^a   Wein, Alan J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIPHENHYDRAMINE; DIURETIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HYOSCYAMINE; MONOAMINE OXIDASE INHIBITOR; NARCOTIC AGENT; NEUROLEPTIC AGENT; OXYBUTYNIN; PHENOTHIAZINE DERIVATIVE; PROTEINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SULFANILAMIDE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ERECTILE DYSFUNCTION; HUMAN; INFERTILITY; MICTURITION DISORDER; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; URINARY TRACT DISEASE; UROLITHIASIS;

DRUG THERAPY; EPIDIDYMITIS; HUMANS; IMPOTENCE; INFERTILITY; MALE; PRIAPISM; RETROPERITONEAL FIBROSIS; URINARY BLADDER NEOPLASMS; URINARY CALCULI; URINATION DISORDERS;

EID: 0037308764     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(02)00111-8     Document Type: Review

References (71)

1. El-Badawi P, Schwenk EA. A new theory of the innervation of bladder musculature. J Urol 1974;111:613-5.
2. Awad S, Bruce AW, Carro-Ciampi G, et al. Distribution of alpha and beta adrenoreceptors in human urinary bladder. Br J Pharmacol 1974;50:525-9.
3. Raezer DM, Wein AJ, Jacobowitz D. Autonomic innervation of canine urinary bladder: cholinergic and adrenergic contributions and interaction of sympathetic and parasympathetic nervous systems in bladder function. Urology 1973;2:211-21.
4. Bissada NK, Finkbeiner AE. Neuropharmacology of the lower urinary tract. In: Finkbeiner AE, Barbour GL, Bissada NK, editors. Pharmacology of the urinary tract and the male reproductive system. New York: Appleton-Century-Crofts; 1982.
5. Diokno AC, Lapides J. Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 1972;108(2):307-9.
6. Drake MG, Nixon PM, Crew JP. Drug induced bladder and urinary disorders. Incidence, prevention and management. Drug Saf 1998;19:45-55.
7. Glassman AH, Carino JS, Roose SP. Adverse effects of tricyclic antidepressants: focus on the elderly. Adv Biochem Psychopharmacol 1984;39:391-8.
8. Merrill DC, Markland C. Vesical dysfunction induced by the major tranquilizers. J Urol 1972;107:769-71.
9. Applebaum SM. Pharmacologic agents in micturitional disorders. Urology 1980;16:555-68.
10. Wein AJ. Lower urinary tract function and pharmacologic management of lower urinary tract dysfunction. Urol Clin North Am 1987;14:273-96.
11. Magee MC, Fried FA. Pharmacology of male sexual function. In: Finkbeiner AE, Barbour GL, Bissada NK, editors. Pharmacology of the urinary tract and the male reproductive system. New York: Appleton-Century-Crofts; 1982.
12. Wein AJ, Van Arsdalen K. Drug induced male sexual dysfunction. Urol Clin North Am 1988;15:23-31.
13. Slag MF, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients. JAMA 1983;249:1736-40.
14. Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Walsh PC, Retik AB, Vaughan ED, et al, editors. Campbell's urology. 7th edition. Philadelphia: W. B. Saunders; 1998;1157-80.
15. Goldstein J, Krane RJ. Drug-induced sexual dysfunction. World J Urol 1983;1:239.
16. Greenblatt DJ, Koch-Weser J. Gynecomastia and impotence: complications of spironolactone therapy. JAMA 1973;223:82.
17. Ambrosioni E, Costa FU, Montebugnoli L, et al. Comparison of antihypertensive efficacy of atenolol, oxprenolol and pindolol at rest and during exercise. Drugs 1983;25(Suppl):30.
18. Greminger P, Vetter HH, Boerlin HJ, et al. A comparative study between 100 mg atenolol and 20 mg pindolol slow release in essential hypertension. Drugs 1983;25(Suppl):36.
19. Heel RC, Brodgen RM, Speight TM, et al. Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs 1979;17:425-60.
20. Jensen J, Lendorf A, Stimpel H, et al. The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 1999;12:271-5.
21. Shader RI, Elkin R. The effects of antianxiety and antipsychotic drugs on sexual behavior. Med Probl Pharmacopsychiatry 1980;15:91-110.
22. Wolfe MM. Impotence of cimetidine treatment. N Engl J Med 1979;300:94.
23. Boyarsky S, Boyarsky R. Office treatment of male sexual dysfunction. Urol Clin North Am 1980;7:107-20.
24. Lipman AG. Drugs associated with impotence. Mod Med 1977;45:81.
25. De Mey C. Alpha1-blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials? Euro Urol 2000;38(Suppl 1):25-39.
26. O'Meara J, White WB. Ejaculatory failure and urinary dysfunction secondary to labetalol. J Urol 1988;139:371-72.
27. Seagraves RT, Madsen R, Carter CS, et al. Erectile dysfunction associated with pharmacological agents. In: Seagravesz RT, Schoenberg HW, editors. Diagnosis and treatment of erectile disturbances: a guide for clinicians. New York: Plenum Publishing; 1985;23-63.
28. Pohl J, Pott B, Kleinhans G. Priapism: a three-phase concept of management according to etiology and prognosis. Br J Urol 1986;58:113-118.
29. Rubin SO. Priapism as a probable sequel to medication. Scand J Urol Nephrol 1968;2:81-5.
30. Dorman BW, Schmidt JD. Association of priapism in phenothiazine therapy. J Urol 1976;116:51-3.
31. Jackson SC, Walker JS. Self-administered intraurethral chlorpromazine: an unusual cause of priapism. Am J Emerg Med 1991;9:171-75.
32. Rosen SI, Hanno PM. Clozapine-induced priapism. J Urol 1992;148:876-7.
33. Levenson JL. Priapism associated with bupropion treatment [letter]. Am J Psychiatry 1995;152:813.
34. Mendelson WB, Franko T. Priapism with sertraline and lithium [letter]. J Clin Psychopharmacol 1994;14:434-5.
35. Murray MJ, Hooberman D. Fluoxetine and prolonged erection [letter]. Am J Psychiatry 1993;150:167-8.
36. Saenz de Tejada I, Ware JC, Blanco R, et al. Pathophysiology of prolonged penile erection associated with trazodone use. J Urol 1991;145:60-4.
37. Starcj LC, Talley BJ, Brannan SK. Mesoridazine use and priapism [letter]. Am J Psychiatry 1994;151:946.
38. Tejera CA, Ramos-Lorenzi JR. Priapism in a patient receiving perphenazine [letter]. J Clin Psychopharmacol 1992;12:448-9.
39. Thavundayil JX, Hambalek R, Kin NM, et al. Prolonged penile erections induced by hydroxyzine: possible mechanism of action. Neuropsychobiology 1994;30:4-6.
40. Whalen RK, Whitcomb RW, Crowley Jr WF, et al. Priapism in hypogonadal men receiving gonadotropin releasing hormone. J Urol 1991;145:1051-2.
41. Ekstrom B, Olson AM. Priapism in patients treated with total parenteral nutrition. Br J Urol 1987;59:170-1.
42. Klein EA, Montague DK, Steiger E. Priapism associated with the use of intravenous fat emulsion: case reports and postulated pathogenesis. J Urol 1985;133:857-9.
43. Cosentino MJ, Chey WY, Takihard H, et al. The effects of sulfasalazine on human male fertility potential and seminal prostaglandins. J Urol 1984;132:682-6.
44. Levi AJ, Fisher AM, Hughes L, et al. Male infertility due to sulfasalazine. Lancet 1979;2:276-8.
45. Toovey S, Hudson E, Hendry WF, et al. Sulfazalazine and male infertility: reversibility and possible mechanism. Gut 1981;22:445-51.
46. Toth A. Reversible toxic effect of salicylazosulfapyridine on semen quality. Fertil Steril 1979;31:538-40.
47. Van Thiel DH, Gavaler JS, Smith Jr WI, et al. Hypothalamic-pituitary-gonadal dysfunction in men using cimetidine. N Engl J Med 1979;300:1012-5.
48. Schlegel PN, Chang TS, Marshall FF. Antibiotics: potential hazards to male fertility. Fertil Steril 1991;55:235-42.
49. Timmermans L. Influence of antibiotics on spermatogenesis. J Urol 1974;112:348-9.
50. Nelson WO, Bunge RG. The effect of therapeutic dosages of nitrofurantoin upon spermatogenesis in man. J Urol 1957;77:275.
51. White IG. The toxicity of some antibacterials for bull, ram, rabbit and human spermatozoa. Aust J Exp Biol Med Sci 1954;32:41.
52. Drach GW. Secondary and miscellaneous urolithiasis: medications, urinary diversions, and foreign bodies. Urol Clin North Am 2000;27:269-73.
53. Kubota Y, Nakashima K, Sakai H, et al. Pure silicate fragment in a recurrent stone formed of calcium oxalate. Uril Int 1997;58:192-6.
54. Ettinger B, Oldroyd NO, Sorgel F. Triamterene induced nephrolithiasis. JAMA 1980;244:2443-4.
55. Guevara A, Springmann KE, Drach GW, et al. Triamterene stones and computerized axial tomography. Urology 1986;27:104.
56. Spence JD, Wong DG, Lindsay RM. Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorthiazide. Lancet 1985;ii:73-5.
57. Gentle DL, Stoller ML, Jarrett TW, et al. Protease inhibitor-induced urolithiasis. Urology 1997;50:508-11.
58. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary abnormalities associated with indinavir. Ann Intern Med 1998;127:119-25.
59. Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, et al. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol 1999;161:1082-4.
60. Bruce RG, Munch LC, Hovan AD, et al. Urolithiasis associated with the protease inhibitor indinavir. Urology 1997;50:513-8.
61. Alon US, Scagliotti D, Garola RE. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Peds 1994;125:149-51.
62. Koep L, Zuidemia GD. The clinical significance of retroperitoneal fibrosis. Surgery 1977;81:250-7.
63. Iversen BM, Johannesen JW, Nordahl E, et al. Retroperitoneal fibrosis during treatment with methyldopa. Lancet 1975;2:302-4.
64. Demko TM, Diamond JR, Groff J. Obstructive nephropathy as a result of retroperitoneal fibrosis: a review of its pathogenesis and associations. J Am Soc Neph 1997;8:684-8.
65. Stecker Jr JF, Rawls HP, Devine Jr CJ, et al. Retroperitoneal fibrosis and ergot derivatives. J Urol 1974;112:30-2.
66. Gasparich JP, Mason JT, Greene HL, et al. Non-infectious epididymitis associated with amiodarone therapy. Lancet 1984;2:1211-2.
67. Sadek I, Biron P, Kus T. Amiodarone-induced epididymitis: report of a new case and literature review of 12 cases. Canad J Cardiol 1993;9:833-6.
68. Gabal-Shehab LL, Monga M. Recurrent bilateral amiodarone induced epididymitis. J Urol 1999;161:921.
69. Messing EM, Catalona W. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughan Jr ED, et al, editors. Campbell's urology. 7th edition. Philadelphia: W. B. Saunders; 1998;2327-410.
70. Cohen SM, Garland EM, St. John M, et al. Acrolein initiates rat urinary bladder carcinogenesis. Cancer Res 1992;52:3577-81.
71. Habs MR, Schmahl D. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with uroprotectors sodium 2-mercaptoethane sulfonate (Mesna) and disodium 2.2′-dithio-bis-ethane sulfonate (Dimesna). Cancer 1983;51:606-7.